Scholar Rock Holding Corporation reported the results of its annual stockholder meeting held on June 4, 2026. Stockholders elected four Class II directors—David Hallal, Kristina Burow, Michael Gilman, Ph.D., and Katie Peng—to three-year terms ending at the 2029 annual meeting.
Support for these directors ranged from 86,753,433 to 96,269,103 votes in favor, with 14,598,794 to 24,114,464 votes withheld. Stockholders also ratified Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 113,411,438 votes for, 764,548 against, and 500,031 abstentions.
In addition, stockholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers, with 68,280,961 votes for, 42,455,921 against, and 131,015 abstentions. These outcomes confirm continued stockholder approval of the Company’s board composition, auditor selection, and executive pay program.
Scholar Rock Holding Corporation filing reports that Redmile Group, LLC and related parties hold a combined 9,066,621 shares of Common Stock, representing 7.6% of the class based on 119,103,774 shares outstanding as of March 31, 2026. The filing attributes 9,066,621 shares to Redmile and Jeremy C. Green and 6,907,180 shares to RedCo II Master Fund, L.P.
The schedule clarifies voting and dispositive power is shared for the disclosed shares because they are held by investment vehicles managed by Redmile; Redmile and Mr. Green disclaim beneficial ownership except for any pecuniary interest. The filing is an amendment to a prior Schedule 13G/A and is signed by Jeremy C. Green.
T. Rowe Price Associates, Inc. filed an amendment to a Schedule 13G disclosing 6,206,044 shares of Scholar Rock Holding Corp common stock, representing 5.4% of the class as of 03/31/2026. The filing lists 6,203,887 shares as sole voting power and 6,206,044 as sole dispositive power. The filing is signed by a Vice President on 05/15/2026.
Scholar Rock Holding Corporation reported a larger quarterly net loss as it continues investing in late‑stage neuromuscular programs and launch readiness for apitegromab. For the three months ended March 31, 2026, net loss widened to $105.5 million, compared with $74.7 million a year earlier, driven mainly by higher general and administrative spending linked to commercialization preparation and headcount growth.
Research and development expense rose modestly to $51.8 million, with spending concentrated on apitegromab clinical and regulatory activities and the broader anti‑myostatin pipeline. Scholar Rock strengthened its balance sheet, closing the quarter with $479.9 million in cash, cash equivalents, and marketable securities, helped by an at‑the‑market equity program that raised $111.8 million and by drawing $200 million under a new term loan facility with Blue Owl.
Regulatorily, the company resubmitted its Biologics License Application for apitegromab in SMA in March 2026, which the FDA accepted with a September 30, 2026 PDUFA action date. The resubmission followed a 2025 Complete Response Letter tied to a third‑party fill‑finish facility, not to apitegromab’s efficacy or safety data.
Scholar Rock Holding Corporation furnished an update on its financial and operating results for the quarter ended March 31, 2026. The company issued a press release, provided as Exhibit 99.1, and prepared a corporate presentation, furnished as Exhibit 99.2, in connection with these results.
The slides are being used during a conference call scheduled for 8:00 am ET on May 7, 2026 to discuss the quarter and provide a business update. The press release and slides are designated as furnished, not filed, under the Exchange Act, limiting their use for certain legal purposes.
Scholar Rock Holding Corp director Kristina Burow exercised stock options to acquire 89,800 shares of Common Stock on April 23, 2026 at exercise prices of $8.36, $9.11, $4.75 and $26.78 per share. Following these exercises, she holds 110,871 Common Shares directly, reflecting shares obtained through option exercises with no reported same-day sales. Separately, an entity, ARCH Venture Fund VIII, L.P., holds 2,345,711 Common Shares indirectly associated with Burow; she has an economic interest but no voting or investment control over those shares, which are attributed to ARCH VIII and related ARCH entities.
Scholar Rock Holding Corporation is soliciting proxies for its 2026 virtual Annual Meeting of Stockholders on June 4, 2026 at 12:00 p.m. Eastern Time. Stockholders will elect four Class II directors to serve until 2029, ratify Deloitte & Touche LLP as independent registered public accounting firm for the year ending December 31, 2026, and cast a non-binding advisory vote on executive compensation.
The meeting will be held entirely online via a secure webcast, with voting available by internet, telephone, mail, QR code, or during the meeting using a 16-digit control number. The record date is April 10, 2026, when 119,301,886 shares of common stock were outstanding and entitled to one vote each. The Board recommends voting FOR all three proposals and outlines detailed governance practices, director biographies, committee structures, and director pay, including cash retainers and annual equity grants.
Scholar Rock Holding Corp Chief Operating Officer Keith Woods completed a mandated sale of 10,220 shares of common stock at $49.5745 per share. The sale was executed solely to cover tax withholding obligations arising from the vesting of restricted stock units on April 15, 2026 and was not a discretionary trade.
After this transaction, Woods directly holds 620,055 shares. His equity position also includes 122,021 restricted stock units subject to time-based vesting and 450,000 restricted stock units subject to performance- and time-based vesting, aligning his compensation with future company performance and continued service.
Scholar Rock Holding Corp director and President of R&D Akshay Vaishnaw sold 12,246 shares of common stock in an open-market transaction at $49.5745 per share. According to the disclosure, this sale was mandated solely to cover tax withholding on restricted stock units that vested on April 15, 2026, and was executed as a required “sell to cover” transaction rather than a discretionary trade. After the sale, Vaishnaw directly holds 630,542 shares, along with vested and unvested RSU awards that continue to vest over four years, subject to ongoing service.